A method of treatment of skin tumors in children up to one year

 

(57) Abstract:

The invention relates to medicine, namely to pediatric Oncology, and can be used in complex treatment of children with hemangiomas under the age of one year. The area hemangioma carry out impact monochrome light emission of the red range of the spectrum with a =0.67 microns, labile, non-contact method, by circular movements from the centre to the periphery with the mandatory capture intact surrounding skin tissue within a radius of up to one centimeter. Maximum power of 48 mW. The maximum power flux-density (PPM) 7.5 mW/cm2. Continuous exposure mode. The duration of the procedure for the first session - up to 5 minutes, then the time of filing procedures reduce daily for 10 sec. Just 15-20 procedures, daily, in the morning in the same hours, two courses of treatment with an interval of one to three months. The method allows to achieve the involution and regression of hemangiomas, which lead to the appearance on the site of tumors of soft scars.

The invention relates to medicine, namely to pediatric Oncology, and can be used in complex treatment of children with hemangiomas under the age of one year by phototherapy,a word for the sun. In ancient times it was widely used heliotherapy. Now we can talk about the revival and progress of phototherapy, light therapy, monochromaticity.

It is known that red radiation can cause in humans the development of similar local and systemic compensatory-adaptive processes, it has a stimulating effect on the immune mechanisms and phagocytic reaction cell reticulo-endothelial elements, which leads to anti-inflammatory action. The complex thermal and biochemical reactions that occur in response to red radiation, has a trophic effect, stimulates reparative regeneration of damaged tissues, which is very important for rapid wound healing and ulcers of the skin.

There is a method of treatment of low-energy laser (LLLT), including the red range, with the aim of eliminating pain, accelerate healing of postoperative wounds, stimulation of the immune system (see Durnev L. A., Balakirev, S. A., Guseva, L. I., Grabowski A. J. low-intensity laser irradiation in pediatric Oncohematology //proceedings of the 2 Congress of pediatric oncologists and hematologists Russia, Rostov-nutone, for the prevention of postoperative complications in order to accelerate the healing of postoperative wounds. The authors refer to the use of different magnetic-infrared laser devices, including MILTA” and “RIKTA”. In this work it was noted that treatment of complications with NEELY allows you to accurately observe the modes of medical and surgical treatment, in most cases, to avoid symptomatic purpose anti-inflammatory drugs and analgesics, improves the quality of life of patients during treatment.

However, it should be noted that the possibilities of this method is limited by the fact that LLLT can stimulate growth of the primary tumor and its metastasis. Therefore, the authors use this method in the early postoperative period after removal of the tumor.

Remains relevant to the development of methods to influence tumor body and do not cause the stimulation of tumor growth.

There is a method of treatment of tumors of the skin and visible mucous membranes (A. I. Gusev. “A method of treatment of tumors of the skin and visible mucous membranes" Patent No. 2143237 from 27.12.99. Bul Fig. No. 36 of 27.12 and light therapy is used for 2-20 minutes, with a color range from 400 to 760 nm, which eliminates the monochrome effects, causing the destruction of tissue.

Furthermore, the method has not been applied for treatment of hemangiomas of the skin in children under one year of age peculiarities which must be taken into account.

The aim of the invention is the use in children under one year of age with hemangiomas complicated by ulceration, bleeding, wound infection, light emission of the red range to stimulate processes of purification and epithelialization of the wound and induction processes regression angiomas.

This objective is achieved in that area hemangioma with purulent or clean the wound or place of ulcerated hemangiomas carry out impact monochrome light emission of the red range of the spectrum with a =0.67 microns generated by physiotherapeutic apparatus “Range-LC”, labile, non-contact technique, circular movements from the centre to the periphery with the mandatory capture of intact skin tissue, with a maximum radiated power of 48 mW, the maximum power flux-density (PPM) 7.5 mW/cm2with the filing of the radiation in a continuous mode. The duration of the procedure for the first session not Prelom one to three months. All is 15-20 procedures carried out daily in the morning in the same hours.

The invention of “a Method of treatment of skin tumors in children up to one year is new, because it is unknown the level of medicine in the field of pediatric Oncology in the complex treatment of children with hemangiomas.

Comparative analysis of the claimed solution with the prototype shows that the claimed method differs from the known fact that exposure to light is carried out using a monochrome matrix red color with a =0.67 microns, maximum power of 48 mW, the maximum power flux-density (PPM) 7.5 mW/cm2radiation was applied in a continuous mode, daily changing the exposure time to 10 seconds. The use of such parameters of light has led to the rapid granulation existing wounds, its purification from pus. Starting from the second light therapy session marked the early epithelialization of the wounds, which were fully completed already for the fifth procedure. In tissue hemangioma were registered processes, which we estimated as dry necrosis or regression of the tumor itself. After the last session of the hemangioma was registered education white, soft fibers, ograniczen industrially applicable as it can be used in health care, in health facilities the children's profile as in special cancer research institutes and hospitals medical network.

The specific examples of the application of the Method of treatment of skin tumors in children up to one year” on the sick children

Below are extracts from the histories. In the treatment of children was used userovateley physiotherapy device “Range-LC”, whose purpose is to implement and selective laser led fotohromotherapy (FHT). Exposure was performed using an led matrix is made of a dielectric material with built-in matrices of LEDs for red light with a =0.67 microns. Maximum power of 48 mW, the maximum power flux-density (PPM) 7.5 mW/cm2radiation was applied in a continuous mode. The duration of one for the first session did not exceed 5 minutes, then the time of filing procedures daily decreased by 10 sec. All was done 15-20 procedures carried out daily in the morning in the same hours. Conducted two courses of treatment with an interval of one to three months.

A control group. The child is one-third of the right shoulder. The child was born from the first pregnancy, the weight of 3,700 kg, height 56 see In the first week of a child's life in the upper third of the right shoulder was detected point neoplasm, which rapidly increased in size and in 4 months syazwani.

In the initial examination in RNII: in the upper third of the right shoulder is defined by bright red education - hemangioma with maximum clinicom 60 mm, height 4 mm tumor with ulceration its surface to 3/4 of neoplasms. The patient was prescribed conservative treatment in the form of overlay locally balsamic dressing with ointment “Levomekol”. During a long period the child was marked anxiety, insomnia, weight loss, periodic temperature rise up to 38°C

After nine months hemangioma clinically determined, in its place formed a scar, thickness 60 mm

The group with the FHT. Child of W. 4 months, past medical history, N 622/0. Diagnosis: Congenital growing skin and subcutaneous hemangioma of the right gluteal region with manifestations. The child was born from the first pregnancy, the weight of 3,700 kg and a height of 51 see On the first week of a child's life in the right buttock was detected point neoplasm, motorways locally balsamic ointment dressing. On a background of treatment the child's condition deteriorated: appeared anxiety, sleep disorders, refusal to eat, weight loss, periodically rise of temperature up to +38°C, the zone of increased expression.

In the initial examination in RNII: the area inside of the upper right quadrant of the buttocks in the indent of 1 cm from the anus is bright red lesion, size of 4.8×3.5 cm with pitting its surface to 3/4 of neoplasms. Given the early age of the child, the prevalence of the process, the criticality of localization, the ineffectiveness of previous treatment, the presence of pronounced inflammation in the area of hemangiomas, the use of traditional methods of treatment was impossible. The patient was assigned photogrammetery (FHT) using red light. Sessions photogrammetrie was carried out daily, in the morning at the same time, once the exposure time 5 minutes on each subsequent session reduced the exposure time to 10 seconds. It was originally held 5 sessions FHT, then was given a break and after three months, the patient received 10 sessions FHT.

Treatment results: after the first session FHT wound surface had dried up, after the second session, the wound surface was covered with corales-point enable (syndrome “fly agaric”). All these signs testified to developing hardening of the hemangioma.

After three months, visually almost the entire surface of the hemangioma had a whitish surface, except share 0.8×1.5 cm in pole hemangioma, which retained the red color. We had a second course FHT. At ultrasound examination detected in the right gluteal region hypoechoic mass was 2,39×1.5 cm, when CDG blood was not registered. After the second course FHT on the location of the hemangioma was determined by the formation of white strands, limited border 2 ml width.

The proposed Method of treatment of skin tumors in children under one year were treated in 20 children 3-9 months with a diagnosis of Complicated hemangioma. In 5 children in the hemangioma had noted the presence of an open, infected, purulent wounds with a characteristic fetid odor. In the rest of the group was registered trophic or post-traumatic ulceration, periodically bleeding or giving serosanguineous discharge.

Was observed in a control group of 5 people who were the standard treatment: toilet wounds with antiseptic solution, superimposed bandage with ointment (giochizona, limicola); pickup impact on the wounds hemangiomas accelerates clearance of necrotic masses, reduces more than three days exudative phase of the inflammatory process, at the same time accelerates the development of granulation tissue, normalizes the growth and stimulates the proliferation of fibroblasts. Already on the second day of treatment light managed to cope with ulcerations in hemangiomas. Epithelization of the wound is completed on 5 days earlier than in the control groups.

Everyone treated this way children was marked involution of hemangiomas, which passed successively through the stages, described in detail in the work of Lobyntsevo N. M. (Patent No. 2158536. Bull. No. 31 from 10.11.2002). In the final stages of treatment education are not visually recorded, according to the ultrasound blood flow in them was not determined.

The General condition of the children was significantly improved. They ceased to be nervous, had gained weight, showed an active lifestyle.

Technical and economic efficiency of the method is that the use of the proposed method for the treatment of hemangiomas is ensured in comparison with the existing methods, the following advantages:

the red light of a non-invasive, contactless;

- elimination of the need for special surgery, cryogenic, Gia purulent and clean wounds, trophic ulcers and ulcerations in the field of hemangiomas;

- significant improvement in the condition of children, weight normalization and development;

- stimulation of involution and regression of hemangiomas, leading to the appearance in their place soft scars.

The proposed method for the treatment of skin tumors in children under one year old is industrially applied, because it can be used as a dedicated cancer hospitals and in-patient treatment network.

A method of treatment of skin tumors in children up to one year, including monochrome light emission, wherein an area of the hemangioma with purulent or clean the wound or place of ulcerated hemangiomas affect monochrome light emission of the red range of the spectrum with a =0.67 microns, with a maximum radiated power of 48 mW, with a maximum power flux-density (PPM) 7.5 mW/cm2in continuous mode, physiotherapy apparatus, labile non-contact method by circular movements from the centre to the periphery with the mandatory capture intact surrounding skin tissue within a radius of up to 1 cm, the duration of the procedure for the first session to 5 minutes, then the time of filing procedures ejednevnoi month.



 

Same patents:
The invention relates to medicine, namely to laser ENT surgery
The invention relates to medicine and can be used in maxillo-facial surgery, ENT, dental surgery, physiotherapy

The invention relates to medicine, and is intended for the treatment of bronchial tissue wounds in patients with various diseases of the bronchopulmonary system, underwent reconstructive surgery on the trachea and bronchi
The invention relates to medicine, namely to traumatology and orthopedics, and can be used in the conservative treatment of degenerative-dystrophic diseases of large joints

The invention relates to medicine, namely purulent surgery
The invention relates to medicine, and is intended for the treatment of acute and chronic viral infections
The invention relates to medicine and can be used for the treatment of periodontal disease, complicated by perforation of the bottom of the tooth cavity
The invention relates to medicine and can be used for the treatment and prevention of recurrence of genital human papillomavirus infection (RSI)
The invention relates to medicine, namely to neurosurgery

The invention relates to medicine, namely to photodynamic therapy, and can be used in otolaryngology

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!